JP2012506896A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506896A5
JP2012506896A5 JP2011533714A JP2011533714A JP2012506896A5 JP 2012506896 A5 JP2012506896 A5 JP 2012506896A5 JP 2011533714 A JP2011533714 A JP 2011533714A JP 2011533714 A JP2011533714 A JP 2011533714A JP 2012506896 A5 JP2012506896 A5 JP 2012506896A5
Authority
JP
Japan
Prior art keywords
meta
compound
och
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506896A (ja
JP5490811B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064243 external-priority patent/WO2010049466A1/en
Publication of JP2012506896A publication Critical patent/JP2012506896A/ja
Publication of JP2012506896A5 publication Critical patent/JP2012506896A5/ja
Application granted granted Critical
Publication of JP5490811B2 publication Critical patent/JP5490811B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533714A 2008-10-30 2009-10-29 アポaに対して活性なチエノトリアゾロジアゼピン誘導体 Expired - Fee Related JP5490811B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08167982 2008-10-30
EP08167982.1 2008-10-30
PCT/EP2009/064243 WO2010049466A1 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo a

Publications (3)

Publication Number Publication Date
JP2012506896A JP2012506896A (ja) 2012-03-22
JP2012506896A5 true JP2012506896A5 (cg-RX-API-DMAC7.html) 2012-12-20
JP5490811B2 JP5490811B2 (ja) 2014-05-14

Family

ID=40380148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533714A Expired - Fee Related JP5490811B2 (ja) 2008-10-30 2009-10-29 アポaに対して活性なチエノトリアゾロジアゼピン誘導体

Country Status (11)

Country Link
US (1) US8569288B2 (cg-RX-API-DMAC7.html)
EP (1) EP2362876B1 (cg-RX-API-DMAC7.html)
JP (1) JP5490811B2 (cg-RX-API-DMAC7.html)
KR (1) KR101633742B1 (cg-RX-API-DMAC7.html)
CN (1) CN102292341B (cg-RX-API-DMAC7.html)
AU (1) AU2009309691B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0914406A2 (cg-RX-API-DMAC7.html)
CA (1) CA2741934C (cg-RX-API-DMAC7.html)
EA (1) EA018620B1 (cg-RX-API-DMAC7.html)
ES (1) ES2448567T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010049466A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
CN102427813A (zh) 2009-03-18 2012-04-25 雷斯韦洛吉克斯公司 新的抗炎剂
EP2421533B1 (en) 2009-04-22 2018-10-17 Resverlogix Corp. Novel anti-inflammatory agents
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
BR122014024883A2 (pt) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013184878A1 (en) 2012-06-06 2013-12-12 Constellation Pharmaceuticals, Inc. Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX377534B (es) 2014-02-28 2025-03-10 Tensha Therapeutics Inc Compuestos para usarse en el tratamiento de hiperinsulinemia.
JP6682522B2 (ja) 2014-06-20 2020-04-15 コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. 2−((4s)−6−(4−クロロフェニル)−1−メチル−4h−ベンゾ[c]イソオキサゾロ[4,5−e]アゼピン−4−イル)アセトアミドの結晶形態
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
MX2017001757A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
US10124009B2 (en) 2014-10-27 2018-11-13 Tensha Therapeutics, Inc. Bromodomain inhibitors
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
BR112018009798A8 (pt) * 2015-11-25 2019-02-26 Dana Farber Cancer Inst Inc inibidores de bromodomínio bivalentes e usos dos mesmos
EA202092635A1 (ru) 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
DE3435973A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
DE3878833T2 (de) 1987-05-28 1993-06-09 Yoshitomi Pharmaceutical Thieno(triazolo)diazepinverbindungen, und medizinische verwendung derselben.
CA2230477A1 (en) 1995-09-09 1997-03-13 F. Hoffmann-La Roche Ag Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels
US6444664B1 (en) 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Similar Documents

Publication Publication Date Title
JP2012506896A5 (cg-RX-API-DMAC7.html)
JP2010077141A5 (cg-RX-API-DMAC7.html)
JP2014500861A5 (cg-RX-API-DMAC7.html)
JP2010529147A5 (cg-RX-API-DMAC7.html)
JP2014508811A5 (cg-RX-API-DMAC7.html)
JP2014515013A5 (cg-RX-API-DMAC7.html)
JP2013508279A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
JP2013545785A5 (cg-RX-API-DMAC7.html)
ME02558B (me) Inhibitori replikacije virusa gripa
JP2013544860A5 (cg-RX-API-DMAC7.html)
JP2010509379A5 (cg-RX-API-DMAC7.html)
JP2010527913A5 (cg-RX-API-DMAC7.html)
JP2010501474A5 (cg-RX-API-DMAC7.html)
JP2009535307A5 (cg-RX-API-DMAC7.html)
JP2011519854A5 (cg-RX-API-DMAC7.html)
JP2013513607A5 (cg-RX-API-DMAC7.html)
JP2013542218A5 (cg-RX-API-DMAC7.html)
JP2013503846A5 (cg-RX-API-DMAC7.html)
JP2011504903A5 (cg-RX-API-DMAC7.html)
JP2008533007A5 (cg-RX-API-DMAC7.html)
JP2007302689A5 (cg-RX-API-DMAC7.html)
JP2013533253A5 (cg-RX-API-DMAC7.html)
JP2014505017A5 (cg-RX-API-DMAC7.html)
JP2010090149A5 (cg-RX-API-DMAC7.html)